Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia

Authors :: Ram N. Ganapathi
Cheryl L. Willman
Frederick R. Appelbaum
Jerald P. Radich
John E. Godwin
Eric R. Koegle
Shannon McDonough
Megan Othus
Stephen H. Petersdorf
Anjali S. Advani
Mahrukh K. Ganapathi
Andrew P. Michelson
Alan F. List
Source :: Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020), Scientific Reports
Publication Year :: 2020
Publisher :: Springer Science and Business Media LLC, 2020.
Abstract: Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II α and topo IIβ. In 230 patients with non-M3 AML who received frontline ara-C/daunorubicin we determined expression of topo IIα and topo IIβ by RT-PCR and its relationship to immunophenotype (IP) and outcomes. Treatment outcomes were analyzed by logistic or Cox regression. In 211 patients, available for analysis, topo IIα expression was significantly lower than topo IIβ (P

Tools